Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Mol Cancer Res. 2011 Aug 5;9(10):1406–1417. doi: 10.1158/1541-7786.MCR-11-0227

Figure 4.

Figure 4

Chromatin Immunoprecipitation-qPCR analysis of the Lrig1 enhancer elements. Hormone starved ZR75-1 cells were treated with either vehicle control (VC) or 10 nM E2 for 30 minutes prior to cross-linking. Chromatin immunoprecipitation experiments were carried out using antibodies as indicated and subjected to qPCR with primers against the indicated regions. Enhancer # 1 of Xbp1 served as a positive control. Shown is the mean of three independent replicates with standard deviation. (A) Chromatin immunoprecipitation was performed with antibodies against p300 or ERα. Results are plotted as the fold enrichment of E2 treated cells over vehicle control treated cells. (B) Chromatin immunoprecipitation was performed with antibodies against H3K4me2. Results are plotted as fold enrichment over input DNA for both E2 and control treated cells. (C) Chromatin immunoprecipitation was performed with antibodies against FOXA1. Results are plotted as fold enrichment over input DNA for both E2 and control treated cells.

HHS Vulnerability Disclosure